User login
Key clinical point: A dose of 5 or 10 mg tofacitinib twice daily improved clinical efficacy outcomes compared with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) regardless of baseline body mass index (BMI).
Major finding: The American College of Rheumatology 20/50/70 response rates at 6 months were significantly higher in patients who received 5 or 10 mg tofacitinib vs. placebo (P < .05) and were comparable across baseline BMI (<25, 25 to <30, and ≥30 kg/m2) categories.
Study details: This was a post hoc analysis of six phase 3 trials including 3880 patients with moderate-to-severe RA who were randomly assigned to receive tofacitinib (5 or 10 mg), placebo, or active controls (methotrexate or adalimumab).
Disclosures: The study was sponsored by Pfizer Inc. Several authors reported being on speaker’s bureaus or receiving grants, consulting fees, or other remuneration from various sources, including Pfizer. Five authors reported being employees or shareholders of Pfizer or companies contracting with Pfizer.
Source: Dikranian AH et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: An analysis of pooled data from phase 3 studies. RMD Open. 2022;8:e002103 (May 16). Doi: 10.1136/rmdopen-2021-002103
Key clinical point: A dose of 5 or 10 mg tofacitinib twice daily improved clinical efficacy outcomes compared with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) regardless of baseline body mass index (BMI).
Major finding: The American College of Rheumatology 20/50/70 response rates at 6 months were significantly higher in patients who received 5 or 10 mg tofacitinib vs. placebo (P < .05) and were comparable across baseline BMI (<25, 25 to <30, and ≥30 kg/m2) categories.
Study details: This was a post hoc analysis of six phase 3 trials including 3880 patients with moderate-to-severe RA who were randomly assigned to receive tofacitinib (5 or 10 mg), placebo, or active controls (methotrexate or adalimumab).
Disclosures: The study was sponsored by Pfizer Inc. Several authors reported being on speaker’s bureaus or receiving grants, consulting fees, or other remuneration from various sources, including Pfizer. Five authors reported being employees or shareholders of Pfizer or companies contracting with Pfizer.
Source: Dikranian AH et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: An analysis of pooled data from phase 3 studies. RMD Open. 2022;8:e002103 (May 16). Doi: 10.1136/rmdopen-2021-002103
Key clinical point: A dose of 5 or 10 mg tofacitinib twice daily improved clinical efficacy outcomes compared with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) regardless of baseline body mass index (BMI).
Major finding: The American College of Rheumatology 20/50/70 response rates at 6 months were significantly higher in patients who received 5 or 10 mg tofacitinib vs. placebo (P < .05) and were comparable across baseline BMI (<25, 25 to <30, and ≥30 kg/m2) categories.
Study details: This was a post hoc analysis of six phase 3 trials including 3880 patients with moderate-to-severe RA who were randomly assigned to receive tofacitinib (5 or 10 mg), placebo, or active controls (methotrexate or adalimumab).
Disclosures: The study was sponsored by Pfizer Inc. Several authors reported being on speaker’s bureaus or receiving grants, consulting fees, or other remuneration from various sources, including Pfizer. Five authors reported being employees or shareholders of Pfizer or companies contracting with Pfizer.
Source: Dikranian AH et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: An analysis of pooled data from phase 3 studies. RMD Open. 2022;8:e002103 (May 16). Doi: 10.1136/rmdopen-2021-002103